ZA201408820B - Use of high dose laquinimod for treating multiple sclerosis - Google Patents

Use of high dose laquinimod for treating multiple sclerosis

Info

Publication number
ZA201408820B
ZA201408820B ZA2014/08820A ZA201408820A ZA201408820B ZA 201408820 B ZA201408820 B ZA 201408820B ZA 2014/08820 A ZA2014/08820 A ZA 2014/08820A ZA 201408820 A ZA201408820 A ZA 201408820A ZA 201408820 B ZA201408820 B ZA 201408820B
Authority
ZA
South Africa
Prior art keywords
multiple sclerosis
high dose
treating multiple
laquinimod
dose laquinimod
Prior art date
Application number
ZA2014/08820A
Other languages
English (en)
Inventor
Bar-Zohar Dan
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201408820(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of ZA201408820B publication Critical patent/ZA201408820B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2014/08820A 2012-05-02 2014-12-02 Use of high dose laquinimod for treating multiple sclerosis ZA201408820B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641389P 2012-05-02 2012-05-02
PCT/US2013/039090 WO2013166166A1 (en) 2012-05-02 2013-05-01 Use of high dose laquinimod for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
ZA201408820B true ZA201408820B (en) 2016-06-29

Family

ID=49514859

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/08820A ZA201408820B (en) 2012-05-02 2014-12-02 Use of high dose laquinimod for treating multiple sclerosis

Country Status (21)

Country Link
US (3) US20130303569A1 (OSRAM)
EP (1) EP2844255A4 (OSRAM)
JP (2) JP2015515985A (OSRAM)
KR (1) KR20150013658A (OSRAM)
CN (2) CN105832733A (OSRAM)
AR (1) AR090885A1 (OSRAM)
AU (1) AU2013256352A1 (OSRAM)
BR (1) BR112014027010A2 (OSRAM)
CA (1) CA2870684A1 (OSRAM)
CL (1) CL2014002935A1 (OSRAM)
EA (1) EA201492010A1 (OSRAM)
HK (1) HK1206246A1 (OSRAM)
IL (1) IL235337A0 (OSRAM)
MX (1) MX2014013039A (OSRAM)
PE (1) PE20150161A1 (OSRAM)
PH (1) PH12014502447A1 (OSRAM)
SG (1) SG11201406594UA (OSRAM)
TW (2) TW201804997A (OSRAM)
UY (1) UY34775A (OSRAM)
WO (1) WO2013166166A1 (OSRAM)
ZA (1) ZA201408820B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401330YA (en) 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
US9161935B2 (en) 2012-02-03 2015-10-20 Teva Pharmaceutical Industries, Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy
AR090073A1 (es) 2012-02-16 2014-10-15 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
US20130259856A1 (en) * 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
CA2890194A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AR098924A1 (es) * 2013-12-23 2016-06-22 Teva Pharma Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida
UY36099A (es) * 2014-04-29 2016-02-29 Teva Pharma Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad
WO2017027512A1 (en) * 2015-08-13 2017-02-16 Teva Pharmaceutical Industries Ltd. Use of laquinimod to treat traumatic brain injury
US20190108912A1 (en) * 2017-10-05 2019-04-11 Iquity, Inc. Methods for predicting or detecting disease
JP7724151B2 (ja) * 2018-07-20 2025-08-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 多発性硬化症の治療及び予防方法における使用のための置換されたアミノ－ピリミジン化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
PL1797109T3 (pl) * 2004-09-09 2016-11-30 Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
WO2007146331A1 (en) * 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
HUE026406T2 (en) * 2009-06-19 2016-06-28 Teva Pharma Treatment of multiple sclerosis with laquinimod
EP2523668A1 (en) * 2010-01-13 2012-11-21 Ramot at Tel-Aviv University Ltd Treatment of multiple sclerosis
SG11201401330YA (en) * 2011-10-12 2014-05-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2956137A4 (en) * 2013-02-15 2016-08-03 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD

Also Published As

Publication number Publication date
CA2870684A1 (en) 2013-11-07
EP2844255A1 (en) 2015-03-11
TW201804997A (zh) 2018-02-16
HK1206246A1 (en) 2016-01-08
US20160000775A1 (en) 2016-01-07
PE20150161A1 (es) 2015-02-22
TW201347762A (zh) 2013-12-01
JP2015515985A (ja) 2015-06-04
CN104284663A (zh) 2015-01-14
PH12014502447A1 (en) 2015-01-12
EP2844255A4 (en) 2015-10-14
CL2014002935A1 (es) 2015-03-06
AR090885A1 (es) 2014-12-10
UY34775A (es) 2013-11-29
KR20150013658A (ko) 2015-02-05
BR112014027010A2 (pt) 2017-06-27
SG11201406594UA (en) 2014-11-27
CN105832733A (zh) 2016-08-10
AU2013256352A1 (en) 2014-11-27
WO2013166166A1 (en) 2013-11-07
JP2017222691A (ja) 2017-12-21
US20150265592A1 (en) 2015-09-24
IL235337A0 (en) 2014-12-31
US20130303569A1 (en) 2013-11-14
EA201492010A1 (ru) 2015-06-30
MX2014013039A (es) 2015-02-04

Similar Documents

Publication Publication Date Title
ZA201408820B (en) Use of high dose laquinimod for treating multiple sclerosis
LT2879672T (lt) Derinio terapija, skirta išsėtinės sklerozės gydymui
KR102297388B9 (ko) 대사장애를 치료하기 위한 아커만시아의 용도
IL237138A0 (en) Methods of administration of pirfenidone therapy
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
LT2857019T (lt) Išsėtinės sklerozės gydymo būdas
IL234813A0 (en) Methods for increasing the efficacy of cd37-based therapy
IL227972A0 (en) Use of glycopyrrolate to treat tachycardia
IL240014A0 (en) Treatment of multiple sclerosis using laquinimod
PL2812013T3 (pl) Formulacja do leczenia ibs
PL3524260T3 (pl) Kompozycje farmaceutyczne do leczenia braku apetytu
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
SI2938350T1 (sl) Medicinska formulacija za zdravljenje hiperholesterolemije
GB201214877D0 (en) Compounds for treatments of tumors
IL236718A (en) Vegfr-3 inhibitors for the preparation of drugs for the treatment of liver carcinoma
IL244620A0 (en) A drug combination including laquinimod for the treatment of multiple sclerosis
ZA201409502B (en) Composition for treatment of warts
HK1225291A1 (en) Laquinimod combination therapy for treatment of multiple sclerosis
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
IL228464A (en) Quinolone analogues for use in the preparation of MS drugs